GLP-1 Drugs Linked to 41% Lower Obesity-Cancer Risk in 229,000 Non-Diabetic Patients
Updated
Updated · Medical News Today · Jun 16
GLP-1 Drugs Linked to 41% Lower Obesity-Cancer Risk in 229,000 Non-Diabetic Patients
3 articles · Updated · Medical News Today · Jun 16
Summary
A study of more than 229,000 obese, non-diabetic people found semaglutide- or tirzepatide-based GLP-1 use was associated with a 41% lower overall risk of obesity-related cancers versus diet and exercise counseling.
The analysis covered December 2014 to June 2025, with 38% of participants receiving a GLP-1 prescription and 62% receiving lifestyle counseling, as researchers examined a population increasingly using the drugs for obesity rather than diabetes.
Endometrial cancer showed a 58% lower risk, while multiple myeloma, pancreatic cancer and colorectal cancer also posted risk reductions of 50% or more.
Researchers and outside oncologists said the findings are encouraging but observational, noting possible confounding factors and a median follow-up of only about two years, too short to prove cancer prevention or causation.
The results add to growing interest in GLP-1 effects beyond weight loss, with experts saying any benefit could reflect both sustained weight reduction and direct anti-inflammatory or tumor-related biological effects.
Beyond weight loss, how do GLP-1 drugs directly fight tumors, and could this discovery revolutionize future cancer treatment?
Do the cancer prevention claims for Ozempic outweigh the long-term health risks and the dangers of a booming counterfeit market?
GLP-1 Medications Cut Obesity-Related Cancer Risk by 41%: New Evidence, Disparities, and the Future of Prevention
Overview
Recent research published in June 2026 shows that GLP-1 receptor agonists (GLP-1 RAs), commonly used for weight loss, are linked to a 41% lower risk of obesity-related cancers compared to diet or exercise alone. This large study adds to growing evidence that GLP-1 treatments may reduce cancer risk, suggesting benefits beyond diabetes and weight management. However, while the findings are promising, they do not prove that GLP-1 drugs directly prevent cancer. Experts emphasize that more long-term clinical trials are needed to fully understand how these medications might help prevent cancer.